In January of last year, the University Hospital of Rennes in France released a statement indicating that one person had died and five others were hospitalized following a drug trial. In the weeks that have followed, it has been discovered that the drug being tested was designed to block necessary processes in the human Endocannabinoid Signaling (ECS) system. Read more here.